Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)

Inclusion Criteria: * Onset of symptoms of AMI within six hours prior to randomisation * A twelve-lead electrocardiogram with one of the following: ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or left bundle-branch block * Age ≥ 18 * Informed consent received Exclusion Criteria: * Hypertension defined as blood pressure \> 180/110 mm Hg (systolic BP \>180 mm Hg and/or diastolic BP \>110 mm Hg) on repeated measurements during current admission prior to randomization * Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the preceding 7 days * Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months * Any minor head trauma and any other trauma occurring after onset of the current myocardial infarction * Any known history of stroke or transient ischemic attack or dementia * Any known structural damage of the central nervous system * Prolonged cardiopulmonary resuscitation (\>10 minutes) in the previous two weeks * Current oral anticoagulation * Standard unfractionated heparin (heparin sodium) \>5000 IU or a subcutaneous dose within 6 hours of randomization of a therapeutic dose of any low molecular weight heparin * Known thrombocytopenia (prior platelet count below 100000 cells/μl (100 x10\*\*9/l)) * Known renal insufficiency (prior S-creatinine \>2.5 mg% (\>220 μmol/l) for men and \>2.0 mg% (\>175 μmol/l)) for women * Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential must have a negative pregnancy test, or use a medically accepted method of birth control * Treatment with an investigational drug under another study protocol in the past 7 days * Previous enrollment in this study * Known sensitivity to TNK-tPA, tPA, abciximab, heparin or low molecular weight heparin * Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated * Inability to follow protocol and comply with follow-up requirements